Orient Europharma Valuation
| 4120 Stock | TWD 48.10 0.30 0.63% |
At this time, the company appears to be fairly valued. Orient Europharma holds a recent Real Value of NT$48.98 per share. The prevailing price of the company is NT$48.1. Our model determines the value of Orient Europharma from analyzing the company fundamentals such as Return On Equity of -0.0268, operating margin of (0.01) %, and Shares Outstanding of 86.75 M as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Orient Europharma's price fluctuation is very steady at this time. Calculation of the real value of Orient Europharma is based on 3 months time horizon. Increasing Orient Europharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Orient stock is determined by what a typical buyer is willing to pay for full or partial control of Orient Europharma Co. Since Orient Europharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Orient Stock. However, Orient Europharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 48.1 | Real 48.98 | Hype 48.1 | Naive 47.61 |
The intrinsic value of Orient Europharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Orient Europharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Orient Europharma Co helps investors to forecast how Orient stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Orient Europharma more accurately as focusing exclusively on Orient Europharma's fundamentals will not take into account other important factors: Orient Europharma Total Value Analysis
Orient Europharma Co is presently anticipated to have takeover price of 5.9 B with market capitalization of 3.13 B, debt of 1.68 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Orient Europharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.9 B | 3.13 B | 1.68 B |
Orient Europharma Investor Information
About 65.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.07. In the past many companies with similar price-to-book ratios have beat the market. Orient Europharma last dividend was issued on the 18th of July 2022. The entity had 1160:1000 split on the 28th of July 2010. Based on the key measurements obtained from Orient Europharma's financial statements, Orient Europharma Co is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Orient Europharma Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Orient indicates not a very effective usage of assets in January.Orient Europharma Ownership Allocation
Orient Europharma owns a total of 86.75 Million outstanding shares. Orient Europharma holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.1 pct. of Orient Europharma outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Orient Europharma Profitability Analysis
The company reported the revenue of 4.77 B. Net Income was 120.17 M with profit before overhead, payroll, taxes, and interest of 2.15 B.About Orient Europharma Valuation
Our relative valuation model uses a comparative analysis of Orient Europharma. We calculate exposure to Orient Europharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Orient Europharma's related companies.8 Steps to conduct Orient Europharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Orient Europharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Orient Europharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Orient Europharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Orient Europharma's revenue streams: Identify Orient Europharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Orient Europharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Orient Europharma's growth potential: Evaluate Orient Europharma's management, business model, and growth potential.
- Determine Orient Europharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Orient Europharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Orient Stock Analysis
When running Orient Europharma's price analysis, check to measure Orient Europharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Europharma is operating at the current time. Most of Orient Europharma's value examination focuses on studying past and present price action to predict the probability of Orient Europharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Europharma's price. Additionally, you may evaluate how the addition of Orient Europharma to your portfolios can decrease your overall portfolio volatility.